Identification of a novel small molecule HIF-1α translation inhibitor

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6128-6136

  Narita, Takuhito ^a   Yin, Shaoman ^a   Gelin, Christine F ^b   Moreno, Carlos S ^a   Yepes, Manuel ^a   Nicolaou, K C ^b   Van Meir, Erwin G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; CYSTAMINE DERIVATIVE; ENDOTHELIN 1; ENOLASE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; KC 7 F 2; PROTEIN SYNTHESIS INHIBITOR; PROTEIN SYNTHESIS INHIBITOR KC7F2; S6 KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; GENE ACTIVATION; GENETIC TRANSCRIPTION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TRANSLATION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MODELS, BIOLOGICAL; NEOPLASMS; OXYGEN; PROTEIN BIOSYNTHESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMALL MOLECULE LIBRARIES; SULFONAMIDES;

EID: 70349696534     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3180     Document Type: Article

References (66)

1. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007;26:223-224
2. Gray LH. Radiobiologic basis of oxygen as a modifying factor in radiation therapy. Am J Roentgenol Radium Ther Nucl Med 1961;85: 803-815
3. Amellem O, Pettersen EO. Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif 1991;24:127-141
4. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62: 3387-3394 (Pubitemid 34651384)
5. Kim H, Peng G, Hicks JM, et al. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther 2008;16:599-606. (Pubitemid 351315001)
6. Griguer CE, Oliva CR, Gobin E, et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE2008;3:e3655.
7. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
8. Kaelin WG, Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
9. Graeber TG,Osmanian C, Jacks T, et al. Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91. (Pubitemid 26008141)
10. Shahrzad S, Quayle L, Stone C, et al. Ischemiainduced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. Cancer Res 2005;65: 8134-8141 (Pubitemid 41330576)
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732
12. Weidemann A, Johnson RS. Biology of HIF-1α. Cell Death Differ 2008;15:621-627
13. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008;14:685-698 (Pubitemid 351736449)
14. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118: 1367-1379
15. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004;84:1014-1020 (Pubitemid 39469126)
16. Brennan PA, Zaki GA. Angiogenesis in cancer: the role of endothelin-1. Ann R Coll Surg Engl 2000;82:363-364
17. Guo P, Imanishi Y, Cackowski FC, et al. Upregulation of angiopoietin-2, matrix metalloprotease- 2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 2005;166:877-890 (Pubitemid 40315644)
18. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-919 (Pubitemid 32221783)
19. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J 1998;17:5085-5094 (Pubitemid 28408474)
20. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 1999;59:3915-3918 (Pubitemid 29393552)
21. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia- inducible factor 1α in vascular smooth muscle cells. J Biol Chem 2000;275:26765-26771 (Pubitemid 30688019)
22. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-38211 (Pubitemid 35154674)
23. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin- dependent signaling pathway. J Biol Chem 2002;277:27975-27981 (Pubitemid 34966746)
24. Schmidt MH, Furnari FB, Cavenee WK, Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A 2003;100:6505-6510 (Pubitemid 36666611)
25. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12:363-369 (Pubitemid 32685637)
26. Maynard MA, Ohh M. The role of hypoxiainducible factors in cancer. Cell Mol Life Sci 2007;64:2170-2180
27. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999;274:32631-32637 (Pubitemid 129535289)
28. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013-14019 (Pubitemid 36799945)
29. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5835
30. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-421 (Pubitemid 30626905)
31. Tan C, de Noronha RG, Roecker AJ, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 2005;65:605-612
32. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62: 4316-4324 (Pubitemid 34827288)
33. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-2482
34. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004;6:33-43.
35. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4: 601-605 (Pubitemid 44497213)
36. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-811
37. Zhang H, Qian DZ, Tan YS, et al. Inaugural Article: Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008;105: 19579-19586
38. Belozerov VE, Van Meir EG. Inhibitors of hypoxia- inducible factor-1 signaling. Curr Opin Investig Drugs 2006;7:1067-1076
39. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005;16:901-909
40. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-826
41. Verheul HM, Salumbides B, Van Erp K, et al. Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 2008;14:3589-3597
42. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-688 (Pubitemid 44151605)
43. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8:1801-1807
44. Nicolaou KC, Hughes R, Pfefferkorn JA, Barluenga S, Roecker AJ. Combinatorial synthesis through disulfide exchange: discovery of potent psammaplin A type antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA). Chemistry 2001;7: 4280-4295 (Pubitemid 33724374)
45. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472 (Pubitemid 32335942)
46. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1α and is required for O(2)- independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 2007;25:207-217
47. Pause A, Belsham GJ, Gingras AC, et al. Insulin- dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 1994;371:762-767 (Pubitemid 124000078)
48. Eker P, Pihl A. Studies on the growth-inhibiting and radioprotective effect of cystamine, cysteamine, and AET on mammalian cells in tissue culture. Radiat Res 1964;165-179
49. Jung JH, Sim CJ, Lee CO. Cytotoxic compounds from a two-sponge association. J Nat Prod 1995;58:1722-1726
50. Kim D, Lee IS, Jung JH, Lee CO, Choi SU. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer Res 1999;19:4085-4090
51. ShimJS, Lee HS, Shin J, Kwon HJ. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett 2004;203:163-169 (Pubitemid 38058684)
52. AhnMY, Jung JH, Na YJ, Kim HS. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008; 108:27-33. (Pubitemid 350299431)
53. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124: 471-484
54. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-175
55. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin- insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-1302
56. Peterson RT, Schreiber SL. Translation control: connecting mitogens and the ribosome. Curr Biol 1998;8:R248-50.
57. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307: 1098-1101
58. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2- imidazolyl disulfide and pleurotin inhibit hypoxia- induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-243
59. Lang KJ, Kappel A, Goodall GJ. Hypoxia-inducible factor-1α mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 2002;13:1792-1801 (Pubitemid 34522656)
60. Koh MY, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 2008.
61. Cao Z, Fang J, Xia C, Shi X, Jiang BH. trans- 3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 2004;10:5253-5263
62. Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ. A quassinoid 6α-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4Epho sphorylation. Eur J Pharmacol 2008; 592:41-47
63. Post DE, Devi NS, Li Z, et al. Caner therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004;10:8603-8612 (Pubitemid 40053428)
64. Rong Y, Brat DJ. Vaso-occlusive mechanisms that initiate hypoxia and necrosis in glioblastoma: the role of thrombosis and tissue factor. In: Van Meir EG, editor. CNS cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. New York: Humana Press; 2009. p. 507-528
65. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005;65: 1406-1413 (Pubitemid 40270169)
66. Post DE, Sandberg EM, Devi SN, et al. Targeted cancer-gene therapy using a HIF-dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007;67:6872-6881